Spotlight Growth
No Result
View All Result
Friday, February 3, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

As US and Global Construction Outlooks Remain Strong, This Building Materials Company Could Be a Major Benefactor

by admin
September 3, 2018
in Bio/Med/Pharma, Commodities, Opinion, Sponsored
0
As US and Global Construction Outlooks Remain Strong, This Building Materials Company Could Be a Major Benefactor

One Building Materials Stock To Watch As US and Global Construction Outlooks Remain Strong

Construction activity is often seen as a strong barometer to determine the overall health of the economy. Companies will often put off major construction projects if there is a belief that the economy may be in trouble. Conversely, when economic growth is humming along, construction activity is going to be very lively and active.

According to Statista, United States construction expenditures came in around $1.23 trillion in 2017. This makes the U.S. one of the largest construction markets in the entire world. The market research firm sees a lot of positive trends and factors that will continue to see strong construction growth within the United States. Statista notes that aging U.S. infrastructure is a major issue that will require a significant boost in construction in order to properly update our bridges, roads, and other key public facilities.

Source: Statista
Source: Statista

Overall, Statista estimates that U.S. construction spending will increase from $1.23 trillion in 2017 to $1.53 trillion in 2022. These estimates cover all forms of construction activity, such as residential, non-residential, industrial and more.

On a global scale, the construction industry has strong growth estimates as well. According to an updated report from the Construction Intelligence Center (CIC), the construction research firm rose its forecast for global construction growth.

In December 2017, the CIC released report forecasting that the global construction industry will see growth of 3.6% between 2018 and 2022. However, the CIC released an updated report in April 2018, which increased its growth estimate to 3.7% between 2018 and 2022. While this may not seem like much at first glance, “in real value terms (measured at constant 2017 prices and US$ exchange rates), global construction output is forecast to rise to US$12.4 trillion in 2022 from US$10.4 trillion in 2017,” according to the report.

The global construction boom is fantastic news for companies that supply the necessary building materials needed for construction. As demand for construction increases, so does the demand for building materials. One such company that aims to be a key U.S. building materials supplier is Innovest Global, Inc. (OTC Pink: IVST).

IVST: In Late-Stage Talks, LOI Signed, For Acquiring Building Materials Company With $30 Million Annual Revenue

Innovest Global, Inc. (OTC Pink: IVST) is a Cleveland, Ohio-based conglomerate, which currently has two active divisions: Commercial & Industrial and Biotech & Health Sciences. Innovest’s Commercial & Industrial division is the major revenue growth driver for the company right now, which currently has an annual revenue rate of around $4.5 million, as of the end of August 2018. If the acquisition is completed, the building materials company would be Innovest Global’s third division.

Innovest Global Logo
Innovest Global Logo

On August 31, 2018, Innovest Global announced that it has signed a letter of intent (LOI) and agreed to a final structure for the acquisition of a building materials company that is generating annual revenues of $30 million. Management detailed that the initial discussions began back in March 2018, with formal negotiations beginning in April 2018.

In June, Innovest management formally presented the acquisition pitch to the board of directors of the target company, which later approved and executed the LOI right there on the spot. After two months of further negotiations regarding acquisition transaction structure, both sides were able to reach an agreement.

“Terms include a 100% acquisition of the target entity in exchange for the issuance of 5 million common shares, restricted, with a minimum value guarantee to be achieved in two years, and a high five-figure cash payment at closing. Closing is expected in the first half of September. Look for much more information to come soon,” according to Innovest Global’s official press release.

“This transaction represents a substantial, over five-times increase in Innovest’s revenue, and marks entry into its third industry sector. This is a transformational acquisition for Innovest. Because of the revenue, but also because the leadership of the organization is world class, well respected in their industry, and has a vision and plan for growth that I believe is highly likely to succeed in our model once we hit the switch,” detailed Innovest Global CEO Dan Martin.

IVST: Biotech Division Set For Two Fall Conferences, Featured In Delta Sky Magazine’s October Biotech Issue

Innovest Global’s Biotech & Health Sciences division has been extremely active as well. In late August, the company announced that will be attending two major biotechnology conferences this Fall in an effort to help expand awareness around StemVax Therapeutics.

BIO Investor Forum Logo
BIO Investor Forum Logo

The biotech division, led by Dr. Dwain Morris-Irvin, will be attending the 48th Annual Society for Neuroscience Conference and the BIO Investor Forum. The Society for Neuroscience will take place between November 3-7 in San Diego, California. The BIO Investor Forum will be held in San Francisco, California between October 17-18.

“With the recently announced patent approval, and obtaining exclusive worldwide rights to the technology, we believe that now is the time to collaborate with other scientists that have technologies which serve Innovest’s mission and could benefit from the relationship,” said Dr. Dwain Morris-Irvin, Division President and StemVax Therapeutics Founder.

Source: sfn.org
Source: sfn.org

In other news, Innovest Global will be featured in Delta Sky Magazine’s October Biotech Special Edition issue. The Delta Sky Magazine is the official in-flight magazine for Delta Air Lines, Inc. (NYSE: DAL) and has readership of around six million highly-engaged passengers.

Overall, Innovest Global is continuing to expand its business through key acquisitions and thriving organic sales growth. We expect to hear further details shortly regarding the building materials company and the mega-acquisition that would put Innovest on the radar of even more institutional investors. The Biotech & Health Sciences division should have a very exciting Fall, as the two major conferences and feature in Delta Sky Magazine are on tap in the coming months. Things are really starting to heat up over at Innovest Global.

Disclaimer:

Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.

All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated two thousand five hundred dollars cash and fifty thousand restricted shares for the creation and dissemination of this content.

This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.

The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings.  Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.

Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: https://spotlightgrowth.com//disclosures/

Tags: acquisitionbiopharmaceuticalsbiotechbuilding materialsclevelandcommoditiescommon stockconglomerateemerging growthenergyinvestinginvestmentinvestmentsIVSTLOImedicalMergermicrocap stocksmicrocapsnewsOhiootc marketsotc stocksoutlookpharmaceuticalspublic companyrevenuesalesservicessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstockstradingtreatment
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Elys Game Technology Corp NASDAQ ELYS Completes Acquisition of Engage IT Services Spotlight Growth

Elys Game Technology Corp (NASDAQ: ELYS) Completes Acquisition of Engage IT Services, a Software Engineering and IT Development Company

February 2, 2023
Tenax Therapeutics NASDAQ TENX US Patent Levosimendan PH-HFpEF Spotlight Growth

Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

February 2, 2023
Versus Systems NASDAQ VS Resolve Debt Partner AI Gamification Consumer Debt Spotlight Growth

Versus Systems (NASDAQ: VS) and Resolve Debt Partner to Integrated Generative AI and Gamification to Customer Payments and Credit Markets

February 1, 2023
Finding the Most Accurate Technical Analysis Indicator Spotlight Growth

Finding the Most Accurate Technical Analysis Indicator

January 31, 2023
ADVERTISEMENT

Recent News

Elys Game Technology Corp NASDAQ ELYS Completes Acquisition of Engage IT Services Spotlight Growth

Elys Game Technology Corp (NASDAQ: ELYS) Completes Acquisition of Engage IT Services, a Software Engineering and IT Development Company

February 2, 2023
Tenax Therapeutics NASDAQ TENX US Patent Levosimendan PH-HFpEF Spotlight Growth

Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

February 2, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested